Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma

NCT04870944 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04870944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04870944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 28, 2022
Completion date
December 31, 2026
Enrollment
63 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse midline glioma, h3 k27-altered, metastatic malignant neoplasm in the central nervous system, recurrent diffuse intrinsic pontine glioma, recurrent diffuse midline glioma, h3 k27-altered, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent primary malignant central nervous system neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory primary malignant central nervous system neoplasm